Regulation of energy homeostasis and health consequences in obesity

American Journal of Medicine

Volumn 122, Issue 4 SUPPL. 1, 2009, Pages

  Korner, Judith ^a   Woods, Stephen C ^b   Woodworth, Kristina A ^c  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c SciMantis Communications Inc   (United States)

Author keywords

Endocannabinoids; Gut hormones; Melanocortin system; Metabolic syndrome; Visceral adiposity

Indexed keywords

CARDIOVASCULAR DISEASE; ENERGY METABOLISM; HOMEOSTASIS; HUMAN; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHYSIOLOGY; REVIEW;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; ENERGY METABOLISM; HOMEOSTASIS; HUMANS; OBESITY;

EID: 66149107443     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2009.01.003     Document Type: Article

References (39)

1. Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature. 2000;404:661-671. (Pubitemid 30205071)
2. Lyon CJ, Law RE, Hsueh WA. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology. 2003;144:2195-2200. (Pubitemid 36629866)
3. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr. 2004;92:347-355. (Pubitemid 40277057)
4. Marette A. Mediators of cytokine-induced insulin resistance in obesity and other inflammatory settings. Curr Opin Clin Nutr Metab Care. 2002;5:377-383. (Pubitemid 40684658)
5. Marx J. Cellular warriors at the battle of the bulge. Science. 2003;299: 846-849. (Pubitemid 36182432)
6. Korner J, Aronne LJ. The emerging science of body weight regulation and its impact on obesity treatment. J Clin Invest. 2003;111:565-570. (Pubitemid 36278571)
7. Murphy KG, Bloom SR. Gut hormones and the regulation of energy homeostasis. Nature. 2006;444:854-859. (Pubitemid 46024992)
8. Leibel RL. The role of leptin in the control of body weight. Nutr Rev. 2002;60(pt 2):S15-S19.
9. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactiveleptin concentrations in normal-weight and obese humans. N Engl J Med. 1996;334:292-295. (Pubitemid 26033933)
10. Beglinger C, Degen L, Matzinger D, D'Amato M, Drewe J. Loxiglumide, a CCK-A receptor antagonist, stimulates calorie intake and hunger feelings in humans. Am J Physiol Regul Integr Comp Physiol. 2001;280:R1149-R1154.
11. West DB, Fey D, Woods SC. Cholecystokinin persistently suppresses meal size but not food intake in free-feeding rats. Am J Physiol. 1984;246(pt 2):R776-R787. (Pubitemid 14111438)
12. Korner J, Aronne LJ. Pharmacological approaches to weight reduction: therapeutic targets. J Clin Endocrinol Metab. 2004;89:2616-2621. (Pubitemid 38766340)
13. Di Marzo V, Goparaju SK, Wang L, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature. 2001;410: 822-825. (Pubitemid 32303781)
14. Ravinet Trillou C, Delgorge C, Menet C, Arnone M, Soubrie P. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord. 2004;28:640-648. (Pubitemid 38491158)
15. Cota D, Marsicano G, Tschop M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest. 2003;112:423-431. (Pubitemid 38063771)
16. Kirkham TC, Williams CM, Fezza F, Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol. 2002;136:550-557. (Pubitemid 34717699)
17. Jamshidi N, Taylor DA. Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br J Pharmacol. 2001;134:1151-1154. (Pubitemid 33097243)
18. Cani PD, Montoya ML, Neyrinck AM, Delzenne NM, Lambert DM. Potential modulation of plasma ghrelin and glucagon-like peptide-1 by anorexigenic cannabinoid compounds, SR141716A (rimonabant) and oleoylethanolamide. Br J Nutr. 2004;92:757-761. (Pubitemid 39562153)
19. Pi-Sunyer FX, Aronne LJ, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients, Rio-North America: a randomized controlled trial. JAMA. 2006;295:761-775. (Pubitemid 43244304)
20. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005;365:1389-1397. (Pubitemid 40523733)
21. Després JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005;353:2121-2134. (Pubitemid 41653104)
22. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415-1428. (Pubitemid 40523737)
23. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation. 1998;97:2007-2011. (Pubitemid 28243661)
24. Matias I, Gonthier MP, Orlando P, et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and betapancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab. 2006;91:3171-3180. (Pubitemid 44271774)
25. Pouliot MC, Després JP, Nadeau A, et al. Visceral obesity in men: associations with glucose tolerance, plasma insulin, and lipoprotein levels. Diabetes. 1992;41:826-834.
26. Banerji MA, Faridi N, Atluri R, Chaiken RL, Lebovitz HE. Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men. J Clin Endocrinol Metab. 1999;84:137-144. (Pubitemid 29036692)
27. Heilbronn L, Smith SR, Ravussin E. Failure of fat cell proliferation, mitochondrial function and fat oxidation results in ectopic fat storage, insulin resistance and type II diabetes mellitus. Int J Obes Relat Metab Disord. 2004;28(suppl 4):S12-S21. (Pubitemid 40143844)
28. Hanley AJ, Festa A, D'Agostino RB Jr, et al. Metabolic and inflammation variable clusters and prediction of type 2 diabetes: factor analysis using directly measured insulin sensitivity. Diabetes. 2004; 53:1773-1781. (Pubitemid 38857035)
29. Carey VJ, Walters EE, Colditz GA, et al. Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women: the Nurses' Health Study. Am J Epidemiol. 1997;145:614-619. (Pubitemid 27154864)
30. Pouliot MC, Després JP, Lemieux S, et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol. 1994;73:460-468. (Pubitemid 24096208)
31. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.
32. Iribarren C, Go AS, Husson G, et al. Metabolic syndrome and earlyonset coronary artery disease: is the whole greater than its parts? J Am Coll Cardiol. 2006;48:1800-1807. (Pubitemid 44648627)
33. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735-2752. (Pubitemid 41532612)
34. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). JAMA. 2001;285:2486-2497
35. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005;28:2289-2304. (Pubitemid 41242486)
36. Stern MP, Williams K, Gonzalez-Villalpando C, Hunt KJ, Haffner SM. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care. 2004;27:2676-2681. (Pubitemid 39441469)
37. Grundy SM. Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab. 2007;92:399-404.
38. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEPdefined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003;52:1210-1214. (Pubitemid 36523358)
39. Han TS, Williams K, Sattar N, Hunt KJ, Lean ME, Haffner SM. Analysis of obesity and hyperinsulinemia in the development of metabolic syndrome: San Antonio Heart Study. Obes Res. 2002;10:923-931. (Pubitemid 135688906)